Our Mission

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare neuropsychiatric conditions such as Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q).

In order to achieve this for our patients and stakeholders, we have assembled an experienced and dedicated team at Zynerba; together, we have a proven development and commercialization track record and extensive experience in transdermal delivery, rare diseases and conditions, neurology, and psychiatry.